CHAMPIONS ONCOLOGY, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Other Increases (Decreases) in Period
CHAMPIONS ONCOLOGY, INC. (CSBR) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Other Increases (Decreases) in Period of 0 shares for the 6-month period ending 2012-10-31, per its 10-Q filed 2012-12-13.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod · last filed 2012-12-13
- CHAMPIONS ONCOLOGY, INC. share-based compensation arrangement by share-based payment award, options, other increases (decreases) in period for the quarter ending 2012-10-31 was 0.00 shares.
- CHAMPIONS ONCOLOGY, INC. share-based compensation arrangement by share-based payment award, options, other increases (decreases) in period for the quarter ending 2012-07-31 was 0.00 shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Other Increases (Decreases) in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Other Increases (Decreases) in Period 6 month |
|---|---|---|
| 2012-10-31 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2012-12-13 | 0.00 shares 10-Q · filed 2012-12-13 |
| 2012-07-31 | 0.00 shares 10-Q · filed 2012-09-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |